Your browser doesn't support javascript.
A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting.
Razonable, Raymund R; Pennington, Kelly M; Meehan, Anne M; Wilson, John W; Froemming, Adam T; Bennett, Courtney E; Marshall, Ariela L; Virk, Abinash; Carmona, Eva M.
  • Razonable RR; Division of Infectious Diseases, Mayo Clinic, Rochester, MN. Electronic address: Razonable.raymund@mayo.edu.
  • Pennington KM; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
  • Meehan AM; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN.
  • Wilson JW; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Froemming AT; Department of Radiology, Mayo Clinic, Rochester, MN.
  • Bennett CE; Department of Cardiology, Mayo Clinic, Rochester, MN.
  • Marshall AL; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Virk A; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Carmona EM; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc ; 95(7): 1467-1481, 2020 07.
Article in English | MEDLINE | ID: covidwho-634722
ABSTRACT
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which presents an unprecedented challenge to medical providers worldwide. Although most SARS-CoV-2-infected individuals manifest with a self-limited mild disease that resolves with supportive care in the outpatient setting, patients with moderate to severe COVID-19 will require a multidisciplinary collaborative management approach for optimal care in the hospital setting. Laboratory and radiologic studies provide critical information on disease severity, management options, and overall prognosis. Medical management is mostly supportive with antipyretics, hydration, oxygen supplementation, and other measures as dictated by clinical need. Among its medical complications is a characteristic proinflammatory cytokine storm often associated with end-organ dysfunction, including respiratory failure, liver and renal insufficiency, cardiac injury, and coagulopathy. Specific recommendations for the management of these medical complications are discussed. Despite the issuance of emergency use authorization for remdesivir, there are still no proven effective antiviral and immunomodulatory therapies, and their use in COVID-19 management should be guided by clinical trial protocols or treatment registries. The medical care of patients with COVID-19 extends beyond their hospitalization. Postdischarge follow-up and monitoring should be performed, preferably using telemedicine, until the patients have fully recovered from their illness and are released from home quarantine protocols.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Hospitalization Type of study: Cohort study / Diagnostic study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Mayo Clin Proc Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Hospitalization Type of study: Cohort study / Diagnostic study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Mayo Clin Proc Year: 2020 Document Type: Article